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Porcine reproductive and respiratory syndrome virus (PRRSv) has been endemic for more than 30 
years in most pig producing countries across the globe, and is still one of the most economically 
important pathogens affecting swine. The use of modified live vaccines (MLV) on breeding herds 
has been reported by several investigators and is a common practice in the industry for the control 
of PRRSv. There is limited published information on efficacy of killed virus (KV) vaccines as part 
of PRRS control programs in breeding herds. Thus, the objective of this study was to describe 
productivity losses in breeding herds following PRRS outbreak that used KV vaccination protocol 
compared to those using MLV vaccination protocol. A retrospective observational study was 
conducted to describe the production impact between two exposure groups i.e. KV vaccine-
boostered group (27 herd-outbreaks from 19 herds) and MLV vaccine-treated group (51 herd-
outbreaks from 50 herds). A survey was used to record key demographic information including 
herd size (number of breeding sows in the inventory), location of gilt acclimation site (offsite or 
onsite), PRRS status prior to described outbreak (stable or unstable), frequency of weaning events 
per week (1 and 2 or 3+), PRRSv RFLP type, United States geographic region, and PRRS 
vaccination protocol of breeding sows (KV vaccine, or MLV vaccine). The productivity losses 
were calculated using ‘time to baseline production’ (TTBP), and ‘total loss per thousand sows’ 
(TL/1000 sows). Statistical analyses were performed with SAS version 9.4. There was no 
difference in TTBP between exposure groups (P 0.4242), but the herd-outbreaks in the KV 
vaccine-boostered group had a lower median total loss of 697 per 1000 sows compared to the MLV 
vaccine -treated group (P 0.0021). This study provided information about changes in productivity 
of commercial breeding herds following PRRS outbreak, using KV vaccination protocol as part of 
PRRS management strategy when compared to those using MLV vaccination protocol. 
 
Key words: PRRSv; killed virus vaccine; Modified-live virus vaccine; Time to baseline production; 
Total loss; Swine  
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1. Introduction 
Porcine reproductive and respiratory syndrome virus (PRRSv) has been endemic for more than 30 
years in the global swine industry and continues to cause important economic losses. The 
production losses in the breeding and growing-pig herds resulted in 9.93 million fewer pigs per 
year, or approximately 1.09 billion fewer kilograms of pork (as measured by carcass weight), 
marketed per year in the United States (Holtkamp et al., 2013). Production losses due to PRRSv 
vary widely among herds including death of piglets during pre and post-weaning age, late-term 
abortion, increase in dead and mummified fetuses, weak-born piglets and early farrowing. 
(Christianson et al., 1994). It has been proposed that measuring the change in the number of piglets 
produced is a way to measure of PRRSv infection in the breeding herds (Linhares et al., 2014). 
This method is referred to as a throughout analysis, and captures most of the production losses:- 
breeding herds which have piglet production as the ultimate goal. Thus, it is important to use 
standardized approaches to measure the production losses of the disease when assessing the 
efficacy of exposure options in affected herds. In that regard, the terms time to baseline production 
(TTBP) and total loss per thousand sows attributed to PRRS outbreak (TL/1000 sows) were 
developed to measure production losses due to PRRS in breeding herds (Linhares et al., 2014).  
 
Different strategies have been described to manage PRRSv infection in breeding herds 
without depopulation (Corzo et al., 2010). From those, herd vaccination is commonly adopted as 
part of control and/or elimination protocols (Batista et al., 2003; Dee et al., 1996). Both modified 
live virus (MLV) PRRSv and killed PRRSv vaccines vaccines are used to control the disease. In 
the US swine industry, there are many reports of using PRRSv MLV vaccines (Cano et al., 2007; 
Linhares et al., 2017). However, the currently available commercial vaccines are not capable of 
fully preventing PRRS infection, shedding, or transmission (Diaz et al., 2006; Zuckermann et al., 
2007; Martelli et al., 2009; Darwich et al., 2010; Murtaugh et al., 2011; Geldhof et al., 2012). 
 
Killed PRRSv vaccines have been considered safe and helped PRRSv-infected pigs to 
increase virus-specific antibody responses (Bassaganya-Riera et al., 2004; Kim et al., 2011). Use 
of KV vaccines in a respiratory model could reduce levels of viremia but was not consistent 
(Zuckermann et al., 2007; Nilubol D et al., 2004). Similarly, in reproductive model KV vaccination 
improved the percentage of pigs weaned but could not improve overall reproductive performance 
(Scortti et al., 2007). Repeated administration of KV PRRSv has demonstrated a boostering of 
anti-PRRSv immunity of individual pigs under controlled condition (Nilubol D et al., 2004; 
Zuckermann et al., 2007) and have also showed reduction in median TTBP and TL/1000 sows 
(Rawal et al., 2018). 
 
KV PRRS vaccines have been proposed as a valuable tool to boost the protective immune 
response and demonstrated shorter median TTBP and lower loss of weaned pigs when previously 
immunized with a replicating PRRSv such as live wild-type PRRSv, and/or with MLV PRRSv 
vaccines (Baker et al., 1999; Bassaganya-Riera et al., 2004; Rawal et al., 2019). However, there is 
limited data available from field-based studies on the efficacy of KV vaccines, and/or its 
comparative efficacy to MLV vaccines. Thus, the objective of this study was to describe 
productivity losses from breeding herds using a KV vaccination protocol, as compared to those 
using a MLV vaccination protocol in response to a PRRSv outbreak.  
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2. Materials and methods 
2.1. Study design 
A retrospective observational study was conducted, following breeding herd-outbreaks of 
PRRSv. Data on herd-outbreak was collected on survey filled by the respective herd veterinarian. 
To best of our knowledge, there is not a widely accepted definition of PRRSv outbreak in the swine 
industry. Thus, different vets use slightly different criteria to establish cut off points. Thus, for the 
purpose of this study the definition of PRRSv outbreak was “according to the herd veterinarian 
judgement”, and further validated by having significant production damages (i.e. spikes in aborts 
and/or pre-weaning mortality). 
 
There were 78 herd-outbreaks eligible for this study. The herd-outbreaks were divided into 
two exposure groups i.e. KV vaccine-boostered group, and MLV vaccine-treated group (Fig 1). 
The herd-outbreaks in the KV vaccine-boostered group were vaccinated with MJPRRS® (Phibro 
Animal health corporation) and those in MLV vaccine-treated group were vaccinated with either 
Ingelvac® PRRS ATP (Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO) vaccine, Ingelvac® 
PRRS MLV (Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO) vaccine, or Fostera® PRRSv 
vaccine (Zoetis, Parsippany, NJ, USA). The vaccines were administrated intramuscularly to pigs. 
In the KV vaccine-boostered group there were 27 herd-outbreaks from 19 herds. The MLV 
vaccine-treated group had 51 herd-outbreaks from 50 herds. 
 
Fig 1. Study design. 
 
2.2. Source population and eligibility criteria 
Breed-to-wean herds in the United States were conveniently selected based on an eligibility 
criteria: (a) diagnostic documentation of a PRRS outbreak; (b) use of PRRSv MLV vaccine, and/or 
use of PRRSv KV vaccines in the breeding herd; (c) available open reading frame (ORF)-5 
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* Eligible outbreaks defined as a PRRS outbreak reported by herd veterinarian + significant spike in aborts or PWM
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sequence from the PRRS outbreak; (d) producer agreement to share weekly production records for 
52 weeks before, and up to 52 weeks after the PRRS outbreak; (e) willingness of producer to share 
information on herd demographics, and use of immunologic solutions (exposure to PRRSv live, 
attenuated or, killed) in the herd, confirmed by completing a survey; (f) not experiencing a porcine 
epidemic diarrhea virus (PEDv) outbreak during the study period.  
 
2.3. Data collection 
Data collection occurred between June 1, 2017 to March 31, 2018. Veterinarians and 
producers were contacted to participate in the study by completing a survey via phone calls, email 
and visits. The survey contained key herd demographic information including herd size (number 
of breeding sows in the inventory), location of gilt acclimation site (offsite or on site), United 
States region (midwest or southeast), PRRS status prior to described outbreak (stable or unstable), 
frequency of weaning events per week (1 and 2 or 3+), and PRRS vaccination protocol of breeding 
sows (KV vaccine or MLV vaccine). 
 
2.4. Sample size calculation 
Assuming a standard deviation of 6 weeks in TTBP (Linhares et al., 2014), 18 herd-
outbreaks per exposure group were required to detect a minimum difference of 4 weeks between 
exposure groups at alpha level of 0.05 and power of 80%. 
 
2.5. Exposure groups, and key co-variates of interest 
There were two exposure groups: (i) the KV vaccine-boostered group consisted of herd-
outbreaks that implemented whole-herd immunization with KV vaccine after previous exposure 
to a replicating PRRSv, including MLV vaccine, live PRRSv inoculation, or feedback materials 
(tissues, serum or fecal materials). The (ii) PRRS MLV vaccine-treated group consisted of herd-
outbreaks that reported use of a commercial PRRSv MLV vaccine, with or without combination 
with live virus inoculation or feedback materials. The herd-outbreaks in the MLV vaccine-treated 
group did not report the use of any KV vaccine.  
 
The PRRSv restriction fragment length polymorphism (RFLP) type for each herd-outbreak 
was reported in the survey by the attending herd veterinarians. The PRRS status prior to described 
outbreak was classified for each outbreak as stable (positive stable or negative) or unstable 
(positive unstable) based on American Association of Swine Veterinarians (AASV) classification 
of herds (Holtkamp et al., 2011). Briefly, PRRS stable herds consisted of those without evidence 
of PRRSv RNA detection in suckling piglets by RT-PCR testing, and PRRS unstable herds 
consisted of those with diagnostic evidence of PRRSv viremia in the suckling pig population. 
 
2.6. Outcome variables 
The exposure groups were compared using time to baseline production (TTBP) and total 
loss per thousand sows (TL/1000 sows) as previously established (Linhares et al., 2014). TTBP 
was defined as time in weeks to recover the level of ‘weaned pigs per week’ that the herd had prior 
to the PRRSv outbreak. The TTBP calculation was done using the exponentially weighted moving 
average (EWMA) control chart method (Montgomery, 2012), which is a type of statistical process 
control. The parameter of EWMA control chart were measured based on intention of operating 
with a low false alarm rate and used weight (λ) of 0.40 and a multiple of sigma (σ) of 3 for control 
limits (Krieter et al., 2009). 
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The “TL/1000 sows” was measured by reporting the number of pigs not weaned per 1,000 sows 
between the time of PRRS detection and herd reaching baseline production (TTBP). The 
calculation was done by adding the sum number of pigs weaned below the expected value from 
the time of reporting PRRSv outbreak to TTBP status achievement.  
 
2.7. Statistical analyses 
 Herds were censored if dropped from this study between enrollment and reaching TTBP, 
or at 52 weeks if not reaching TTBP by then. The outcomes (TTBP and TL/1000 sows) were 
calculated for each herd-outbreak. Descriptive analysis was done to report demographic 
characteristics of herd-outbreak(s) using t-test for continuous variables and chi-square for 
frequencies of categorical variables between exposure groups. 
 
Survival analyses were used to compare TTBP between exposure groups. More 
specifically, Kaplan-Meier log-rank test was used for univariate analysis, and Cox proportional 
hazards regression was used on the multivariate analysis. To adjust the analysis for the effect of 
other potentially confounding factors, the effect of the co-variates on the outcome variables was 
investigated. Factors associated with the outcomes (TTBP or TL/1000 sows) at P < 0.200 in the 
univariate analysis were entered in the multivariate model, and non-significant factors (P > 0.05) 
were removed by backward-selection procedure. The vaccine exposure factor (main effect) was 
forced into all multivariate models. Major model assumptions including proportional hazards for 
Cox regression, normality for residuals for GLM, and linear relationship for numerical predictors 
were tested. All statistical analyses were performed with SAS 9.4 software (SAS Institute Inc., 
Cary, North Carolina).  
 
3. Results 
The study included 78 eligible herd-outbreaks (Table 1). 
 
 Table 1 - Baseline demographic characteristics of the eligible outbreaks enrolled in the study.  
 





Characteristics Exposure groups 
KV vaccine -boostered  MLV vaccine-treated 
Number of outbreaks 27 51 
Herd size (mean ± SE) 2918 ± 1198a 2531 ± 1129a 
Weaning frequency 1 and 2/week: 10 (37%)a 1 and 2/week: 40 (78%)b 
3+/week: 17 (63%)a 3+/week: 11 (22%)b 
Gilt acclimation site Offsite: 11 (41%)a Offsite: 38 (75%)b 
Onsite: 16 (59%)a Onsite: 13 (25%)b 
Prior PRRS status  Unstable: 3 (11%)a Unstable: 10 (20%)a 
Stable: 24 (89%)a Stable: 41 (80%)a 
US Region Midwest: 27 (100%)a Midwest: 13 (26%)b 
Southeast: 0 (0%)a Southeast: 38 (74%)b 
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3.1. TTBP  
All the herd-outbreaks reached TTBP by 30 weeks as shown in figure 2.  
 
Fig 2. EVMA control chart illustrating time-to-baseline production (TTBP). Y-axis describing 
TTBP probability from 0-100%; X-axis describing TTBP in weeks from 0-30 weeks. The blue line 
representing killed virus (KV) vaccine boostered group and red line representing modified live 
virus (MLV) vaccine treated group. Pairwise log rank test between two groups not statistically 
significant (P= 0.0505). 
 
The median TTBP of the herd-outbreaks in the KV vaccine-boostered group was 13 weeks 
with an interquartile range (25th to 75th percentile) of 0-18 weeks. The median TTBP of the herd-
outbreaks in MLV vaccine-treated group was 19 weeks with an interquartile range of 13-22 weeks. 
The difference between the two exposure groups was not statistically significant in the univariate 
(P 0.0505) as well as in the multivariate analysis (P 0.4242). 
 
Univariate analysis 
The KV vaccine-boostered group had a trend of shorter TTBP compared to MLV vaccine-
treated group by 6 weeks (P 0.0505) as shown in Table 2.  
 
Table 2 - Comparison of TTBP and TL/1000 sows  





Median TTBP (in weeks) (25th and 75th 
percentile) 
13a (0, 18) 19a (13, 22) 0.0505 
Median TL/1000 sows (25th and 75th 
percentile) 
231a (0, 1897) 1845b (1154, 2964) 0.0003 
Different superscripts indicate statistical significance at P<0.05 between groups on log rank and 
Wilcoxon test for TTBP and TL/1000 sows, respectively 
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The univariate analysis of co-variates revealed that there was a shorter TTBP when herd-
outbreaks: had a weaning event 3+ per week (P< 0.0001), herd size ≤ 8000 (P< 0.0001), onsite gilt 
acclimation site (P< 0.0001), herd-outbreaks from midwest region (P< 0.0001), and unstable PRRS 




The final TTBP multivariate model, included frequency of weaning events per week (P 
0.0122). After adjusting for frequency of weaning events per week, there was no difference in 
TTBP between exposure groups (P 0.4242). 
 
3.2. Total loss outcome 
The median TL/1000 sows of the herd-outbreaks in the KV vaccine-boostered group was 
231 pigs with an interquartile range (25th to 75th percentile) of 0-1897 pigs. The median TL/1000 
sows of the herd-outbreaks in MLV vaccine-treated group was 1845 pigs with an interquartile 
range of 1154-2964 pigs. The difference between the two exposure groups was statistically 
significant in both the univariate and multivariate analysis at (P 0.0003) as shown in figure 3 and 
(P 0.0021). 
 
Fig 3. Box plot showing total loss in the weaned pigs per 1000 sows. Y-axis describing number of 
pigs loss from 0-8000. The blue box representing killed virus (KV) vaccine boostered group and 
red box representing modified live virus (MLV) vaccine treated group. Wilcoxon test between two 
groups showing statistical significant difference in TL/1K sows (P= 0.0003). 
 
Univariate analysis 
The herd-outbreaks using KV vaccination protocol had significantly fewer losses 
compared to herd-outbreaks utilizing MLV protocol (P 0.0003) as shown in Table 2. The 
univariate analysis of co-variates showed that there were fewer TL per thousand sows when herd-
outbreaks: had frequency of weaning events 3+ per week (P 0.0003), followed KV vaccination 
protocol in sows (P 0.0003), herd-outbreaks from mid-west region (P< 0.0001), herd size ≤ 8000 
(P< 0.0007, had onsite gilt acclimation site (P< 0.0001), and had an unstable PRRS status prior to 
the outbreak (P< 0.0001) were significant, independent of the exposure (sow exposure). 
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Multivariate analysis 
The final TL/1000 sows multivariate model included frequency of weaning events 3+ per 
week (P < 0.0001), PRRS vaccination protocol in sows (P 0.0130) and unstable PRRS status prior 
(P 0.0411).  
 
Adjusting for weekly weaning frequency and prior PRRS status, the herd-outbreaks in the 
KV vaccine-boostered group had a median total loss that was 697 pigs per 1000 sows lower 
compared to the MLV-treated group (P 0.0021). The herd-outbreaks with the frequency of weaning 
events 3+ per week experienced lower losses, reporting 982 fewer pigs per 1000 sows respectively 
compared to herd-outbreaks weaning ≤ 2 times per week. The herd-outbreaks with prior PRRS 
status before an outbreak as unstable had a lower loss by 599 pigs per 1000 sows when compared 
with herd-outbreaks with stable prior PRRS status. 
 
4. Discussion 
This was an observational retrospective study characterizing the herd-level outcomes of 
PRRSv infection on U.S. breeding herds adopting different immunologic solutions on the breeding 
herd.  To the best of our knowledge, this is the first peer reviewed manuscript comparing the 
change in productivity in the breeding herds adopting KV or MLV vaccination protocols following 
PRRSv outbreak under field conditions. The metrics used to report the outcomes were time to 
baseline production (TTBP) and total loss per thousand sows (TL/1000 sows). These metrics 
together provide applied information for veterinarians and producers to aid in understanding and 
making informed decision regarding health interventions in breeding herds that become infected 
with PRRSv (Linhares et al., 2014). 
 
On the univariate analysis, the study reported a TTBP 6 weeks shorter (P 0.0505) for 
outbreaks in the KV vaccine-boostered group as compared to those in the MLV group. This was 
nearly statistically significant. However, after adjusting for significant co-variates, there was no 
difference of TTBP between exposure groups (P 0.4242).  
 
In the final model, after adjusting for weekly weaning frequency and prior PRRS status the 
herd outbreaks in the KV vaccine-boostered group had a lower median total loss of 697 per 1000 
sows compared to the MLV-treated group (P 0.0021).  
 
The advantage observed in the KV vaccine-boostered group may be due to an immunologic 
boosting effect of killed PRRSv vaccination. As reported by various research groups, repeated 
administration of a KV vaccine was capable of boosting anti-PRRSv immunity as demonstrated 
by increase in serum neutralizing antibodies and interferon gamma cells (Zuckermann et al., 2007; 
Nilubol D et al., 2004). It has been reported that exposure of KV vaccine to sows and gilts, 
increased the serum neutralizing antibodies which are important immune response for viremia 
clearance and protective immunity against PRRSv infection (Joo et al., 1999; Osorio et al., 2002).  
 
Another study showed that KV vaccine administered to pigs with previous PRRSv 
exposure to MLV or natural infection, induced greater serum neutralizing antibody response 
(Baker et al., 1999). Thus, it is within reason to speculate that higher serum neutralizing antibodies 
in pigs can potentially lower TL/1000 sows and shorten TTBP. The shorter TTBP and lower 
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TL/1000 sows in the KV vaccine-boostered group may have been due to other factors such as 
PRRS virus selection process, and vaccine adjuvant.  
 
This retrospective observational study showed that the herd-outbreaks with frequency of 
weaning events 3+ per week had a shorter TTBP and lower TL/1000 sows when compared to the 
herds with the frequency of weaning events 1 and 2 per week which is in agreement with what has 
been reported in another study (Linhares et al., 2017). This study also found that the herd-outbreaks 
with an unstable prior PRRS status before an outbreak had a lower TL/1000 sows compared to 
herd-outbreaks with a stable PRRS status prior to an outbreak which could be due to presence of 
the underlying immunity against PRRSv in those unstable herds prior to a PRRSv outbreak. As 
revealed by Murtaugh et al. (2002) previously infected pigs develop immunity to PRRSv faster 
than pigs infected for the first time.  
 
Some of the limitations of this study are that being retrospective study, it was not possible 
to compare directly between two exposure group other risk factors may be present that were not 
addressed; herd immunity level of herd-outbreaks may not have been completely comparable 
between the two exposure groups; the analysis was done in herd-outbreak(s) rather than herds 
hence outbreaks from same herds were not independent; and there was no group consisting of no 




In the multivariate model, after adjusting for frequency of weaning events per week, there 
was no difference in TTBP between exposure groups (P 0.4242). However, for TL per 1000 sows 
after adjusting for weekly weaning frequency and prior PRRS status the herd-outbreaks the KV 
vaccine-boostered group had a lower median total loss of 525 per 1000 sows compared to the 
MLV-treated group (P 0.0130). A prospective field study is needed to further clarify the role of 
KV vaccination protocols on herd-level metrics of PRRS control including time to produce 
PRRSv-negative pigs at weaning, TTBP and total loss. 
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